Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Irwin

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
British Journal of Pharmacology|April 6, 2021
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligandsNeil Tanday, Peter R Flatt, Nigel Irwin
The British Journal of Nutrition|January 21, 2012
Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed miceNigel Irwin, Ian A Montgomery, Peter R Flatt
Current Opinion in Endocrinology, Diabetes, and Obesity|January 4, 2021
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Peptides|June 2, 2024
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?Ryan A Lafferty, Peter R Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy|March 17, 2023
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapyRyan A Lafferty, Peter R Flatt, Nigel Irwin
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 9, 2007
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) miceNigel Irwin, Paula L McClean, Peter R Flatt
Clinical Medicine Insights. Endocrinology and Diabetes|February 18, 2022
Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An UpdateEthan S Palmer, Nigel Irwin, Finbarr Pm O'Harte
Diabetes/Metabolism Research and Reviews|April 11, 2018
Emerging therapeutic potential for xenin and related peptides in obesity and diabetesSarah L Craig, Victor A Gault, Nigel Irwin
Currents in Pharmacy Teaching & Learning|May 17, 2018
Association between attendance and overall academic performance on a module within a professional pharmacy degreeNigel Irwin, Kathryn M Burnett, Paul A McCarron
Biological Chemistry|January 1, 2008
Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated isletsRoslyn S Cassidy, Nigel Irwin, Peter R Flatt
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
British Journal of Pharmacology|April 6, 2021
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligandsNeil Tanday, Peter R Flatt, Nigel Irwin
The British Journal of Nutrition|January 21, 2012
Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed miceNigel Irwin, Ian A Montgomery, Peter R Flatt
Current Opinion in Endocrinology, Diabetes, and Obesity|January 4, 2021
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Peptides|June 2, 2024
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?Ryan A Lafferty, Peter R Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy|March 17, 2023
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapyRyan A Lafferty, Peter R Flatt, Nigel Irwin
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 9, 2007
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) miceNigel Irwin, Paula L McClean, Peter R Flatt
Clinical Medicine Insights. Endocrinology and Diabetes|February 18, 2022
Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An UpdateEthan S Palmer, Nigel Irwin, Finbarr Pm O'Harte
Diabetes/Metabolism Research and Reviews|April 11, 2018
Emerging therapeutic potential for xenin and related peptides in obesity and diabetesSarah L Craig, Victor A Gault, Nigel Irwin
Currents in Pharmacy Teaching & Learning|May 17, 2018
Association between attendance and overall academic performance on a module within a professional pharmacy degreeNigel Irwin, Kathryn M Burnett, Paul A McCarron
Biological Chemistry|January 1, 2008
Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated isletsRoslyn S Cassidy, Nigel Irwin, Peter R Flatt
Pageof 17